SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review

Abhishek Kansara; Faiza Mubeen; Jawairia Shakil

doi:10.14797/mdcvj.1120

SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review

Abhishek Kansara, Faiza Mubeen, Jawairia Shakil

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Sodium-glucose transport protein 2 inhibitors, commonly referred to as SGLT2i, are a group of prescription pharmaceuticals that are approved by the United States Food and Drug Administration for use with diet and exercise to lower blood glucose in adults with type 2 diabetes. Diabetes is a well-recognized major contributor to cardiovascular and renal disease burden. In addition to blood glucose control, SGLT2i have been shown to provide significant cardiovascular and renoprotective benefits in patients with and without diabetes. In this review, we describe current evidence related to the renal and cardiovascular benefits of using SGLT2i.

Original language	English (US)
Pages (from-to)	62-72
Number of pages	11
Journal	Methodist DeBakey cardiovascular journal
Volume	18
Issue number	4
DOIs	https://doi.org/10.14797/mdcvj.1120
State	Published - 2022

Keywords

DKA
SGLT2 inhibitors
cardiovascular outcomes
diabetic ketoacidosis
heart failure
renal outcomes
Humans
Blood Glucose
Renal Insufficiency, Chronic/complications
Sodium-Glucose Transporter 2 Inhibitors/adverse effects
Diabetes Mellitus, Type 2/complications
Heart Diseases
Adult
Pharmaceutical Preparations

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.14797/mdcvj.1120

Cite this

@article{ffb275d3f8b1432e95c7e2610b438c95,

title = "SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review",

abstract = "Sodium-glucose transport protein 2 inhibitors, commonly referred to as SGLT2i, are a group of prescription pharmaceuticals that are approved by the United States Food and Drug Administration for use with diet and exercise to lower blood glucose in adults with type 2 diabetes. Diabetes is a well-recognized major contributor to cardiovascular and renal disease burden. In addition to blood glucose control, SGLT2i have been shown to provide significant cardiovascular and renoprotective benefits in patients with and without diabetes. In this review, we describe current evidence related to the renal and cardiovascular benefits of using SGLT2i.",

keywords = "DKA, SGLT2 inhibitors, cardiovascular outcomes, diabetic ketoacidosis, heart failure, renal outcomes, Humans, Blood Glucose, Renal Insufficiency, Chronic/complications, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, Diabetes Mellitus, Type 2/complications, Heart Diseases, Adult, Pharmaceutical Preparations",

author = "Abhishek Kansara and Faiza Mubeen and Jawairia Shakil",

note = "Copyright: {\textcopyright} 2022 The Author(s).",

year = "2022",

doi = "10.14797/mdcvj.1120",

language = "English (US)",

volume = "18",

pages = "62--72",

journal = "Methodist DeBakey cardiovascular journal",

issn = "1947-6094",

publisher = "Methodist DeBakey Heart & Vascular Center",

number = "4",

}

TY - JOUR

T1 - SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease

T2 - A Literature Review

AU - Kansara, Abhishek

AU - Mubeen, Faiza

AU - Shakil, Jawairia

PY - 2022

Y1 - 2022

N2 - Sodium-glucose transport protein 2 inhibitors, commonly referred to as SGLT2i, are a group of prescription pharmaceuticals that are approved by the United States Food and Drug Administration for use with diet and exercise to lower blood glucose in adults with type 2 diabetes. Diabetes is a well-recognized major contributor to cardiovascular and renal disease burden. In addition to blood glucose control, SGLT2i have been shown to provide significant cardiovascular and renoprotective benefits in patients with and without diabetes. In this review, we describe current evidence related to the renal and cardiovascular benefits of using SGLT2i.

AB - Sodium-glucose transport protein 2 inhibitors, commonly referred to as SGLT2i, are a group of prescription pharmaceuticals that are approved by the United States Food and Drug Administration for use with diet and exercise to lower blood glucose in adults with type 2 diabetes. Diabetes is a well-recognized major contributor to cardiovascular and renal disease burden. In addition to blood glucose control, SGLT2i have been shown to provide significant cardiovascular and renoprotective benefits in patients with and without diabetes. In this review, we describe current evidence related to the renal and cardiovascular benefits of using SGLT2i.

KW - DKA

KW - SGLT2 inhibitors

KW - cardiovascular outcomes

KW - diabetic ketoacidosis

KW - heart failure

KW - renal outcomes

KW - Humans

KW - Blood Glucose

KW - Renal Insufficiency, Chronic/complications

KW - Sodium-Glucose Transporter 2 Inhibitors/adverse effects

KW - Diabetes Mellitus, Type 2/complications

KW - Heart Diseases

KW - Adult

KW - Pharmaceutical Preparations

UR - http://www.scopus.com/inward/record.url?scp=85138269594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138269594&partnerID=8YFLogxK

U2 - 10.14797/mdcvj.1120

DO - 10.14797/mdcvj.1120

M3 - Review article

C2 - 36132575

AN - SCOPUS:85138269594

SN - 1947-6094

VL - 18

SP - 62

EP - 72

JO - Methodist DeBakey cardiovascular journal

JF - Methodist DeBakey cardiovascular journal

IS - 4

ER -

SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this